MDTFEA

Uses your system voice; voice and rate in settings.

Snapshot

≈ 3 min read

Names in other languages

No names in other languages are held for this entry yet.

Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.

MDTFEA, also known as 3,4-methylenedioxy-N-(2,2,2-trifluoroethyl)amphetamine, is a chemical compound and possible psychoactive drug of the phenethylamine, amphetamine, and MDxx families related to the entactogen MDEA. It is the derivative of MDEA in which the ethyl group on the amine has been replaced with a trifluoroethyl group. Alexander Shulgin briefly described MDTFEA in his book PiHKAL (Phenethylamines I Have Known and Loved). Based on personal communication to Shulgin, it was described as "possibly active". The drug was tested at a highest total dose of 500 mg orally, which was given in three divided doses over a period of 5 or 6 hours. The effects included only a very mild intoxication and little or no sympathomimetic effects, with these possible effects being short-lasting. For comparison, MDEA has a listed dose of 100 to 200 mg orally and a duration of 3 to 5 hours. Daniel Trachsel has said that MDTFEA seems to be inactive. The chemical synthesis of MDTFEA has been described. MDTFEA was first described in the scientific literature by Shulgin in PiHKAL in 1991. It was not synthesized or tested by Shulgin but was instead described to him via personal communication.

MDTFEA, also known as 3,4-methylenedioxy-N-(2,2,2-trifluoroethyl)amphetamine, is a chemical compound and possible psychoactive drug of the phenethylamine, amphetamine, and MDxx families related to the entactogen MDEA. It is the derivative of MDEA in which the ethyl group on the amine has been replaced with a trifluoroethyl group. Alexander Shulgin briefly described MDTFEA in his book PiHKAL (Phenethylamines I Have Known and Loved). Based on personal communication to Shulgin, it was described as "possibly active". The drug was tested at a highest total dose of 500 mg orally, which was given in three divided doses over a period of 5 or 6 hours. The effects included only a very mild intoxication and little or no sympathomimetic effects, with these possible effects being short-lasting. For comparison, MDEA has a listed dose of 100 to 200 mg orally and a duration of 3 to 5 hours. Daniel Trachsel has said that MDTFEA seems to be inactive. The chemical synthesis of MDTFEA has been described. MDTFEA was first described in the scientific literature by Shulgin in PiHKAL in 1991. It was not synthesized or tested by Shulgin but was instead described to him via personal communication.

Text derived from https://en.wikipedia.org/w/index.php?oldid=1341023352 under CC BY-SA 4.0; modifications have been made.

Sources cited in this revision

1 named source(s) extracted from the cited revision. A source with no author is shown by its publication; nothing is invented.